Literature DB >> 15690129

Inhibition of human neuroblastoma cell growth by CAY10404, a highly selective Cox-2 inhibitor.

Bhupesh Parashar1, Sai Latha Shankar, Kathleen O'Guin, James Butler, Bhadrasain Vikram, Bridget Shafit-Zagardo.   

Abstract

Neuroblastomas constitute about 10% of childhood cancers and are responsible for 15% of pediatric cancer mortality. We evaluated the efficacy and the mechanism of cell death induced by CAY10404, a selective cyclooxygenase-2 (Cox-2) inhibitor in four human neuroblastoma cell lines (SH-EP, SH-SY5Y, SK-N-MC and MSN). Treatment with CAY10404 in the range of 15-115 microM revealed a dose-dependent decrease in cell number and an average IC50 (inhibitory concentration 50%) of 60 microM. About 20-30% of the cells were terminal deoxynucleotidyltransferase-mediated UTP nick-end-labeling (TUNEL) positive 48 h after treatment. Western blot analysis of CAY10404-treated cells showed poly(ADP-ribose) polymerase (PARP) cleavage and cleaved caspase-3 signifying caspase activity and apoptotic cell death. Inhibitor-of-apoptosis proteins including X-linked inhibitor-of-apoptosis protein (XIAP) and survivin did not change significantly after CAY10404 treatment. Fluorescence activated cell sorter (FACS) analysis performed in two different cell lines 48 h following CAY10404 treatment showed a reduction in the number of cells in the G1 phase of the cell cycle and an increase in the number of cells in the G2 phase. When radioresistant SH-EP cells were treated with CAY10404, a 49% decrease in cell viability was observed relative to DMSO-treated cells; pretreatment with CAY10404 followed by ortho-voltage irradiation further enhanced cell death (58%) suggesting radiosensitization by CAY10404.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15690129     DOI: 10.1007/s11060-004-1721-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  29 in total

1.  Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).

Authors:  T D Penning; J J Talley; S R Bertenshaw; J S Carter; P W Collins; S Docter; M J Graneto; L F Lee; J W Malecha; J M Miyashiro; R S Rogers; D J Rogier; S S Yu; E G Burton; J N Cogburn; S A Gregory; C M Koboldt; W E Perkins; K Seibert; A W Veenhuizen; Y Y Zhang; P C Isakson
Journal:  J Med Chem       Date:  1997-04-25       Impact factor: 7.446

2.  Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.

Authors:  S M Fischer; H H Lo; G B Gordon; K Seibert; G Kelloff; R A Lubet; C J Conti
Journal:  Mol Carcinog       Date:  1999-08       Impact factor: 4.784

3.  The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

Authors:  P Prasit; Z Wang; C Brideau; C C Chan; S Charleson; W Cromlish; D Ethier; J F Evans; A W Ford-Hutchinson; J Y Gauthier; R Gordon; J Guay; M Gresser; S Kargman; B Kennedy; Y Leblanc; S Léger; J Mancini; G P O'Neill; M Ouellet; M D Percival; H Perrier; D Riendeau; I Rodger; R Zamboni
Journal:  Bioorg Med Chem Lett       Date:  1999-07-05       Impact factor: 2.823

4.  Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.

Authors:  T Kawamori; C V Rao; K Seibert; B S Reddy
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

5.  Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.

Authors:  M A Molina; M Sitja-Arnau; M G Lemoine; M L Frazier; F A Sinicrope
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

6.  High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma.

Authors:  A Islam; H Kageyama; N Takada; T Kawamoto; H Takayasu; E Isogai; M Ohira; K Hashizume; H Kobayashi; Y Kaneko; A Nakagawara
Journal:  Oncogene       Date:  2000-02-03       Impact factor: 9.867

Review 7.  Mechanisms of caspase activation and inhibition during apoptosis.

Authors:  Yigong Shi
Journal:  Mol Cell       Date:  2002-03       Impact factor: 17.970

8.  Redox status-dependent regulation of cyclooxygenases mediates the capsaicin-induced apoptosis in human neuroblastoma cells.

Authors:  Yong Soo Lee; Eun Jin Kwon; Da Qing Jin; Seung Hee Park; Young Shin Kang; Keun Huh; Jung-Ae Kim
Journal:  J Environ Pathol Toxicol Oncol       Date:  2002       Impact factor: 3.567

9.  Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor.

Authors:  K R Gans; W Galbraith; R J Roman; S B Haber; J S Kerr; W K Schmidt; C Smith; W E Hewes; N R Ackerman
Journal:  J Pharmacol Exp Ther       Date:  1990-07       Impact factor: 4.030

10.  Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.

Authors:  D J Elder; D E Halton; A Hague; C Paraskeva
Journal:  Clin Cancer Res       Date:  1997-10       Impact factor: 12.531

View more
  7 in total

Review 1.  Role of the Survivin gene in pathophysiology.

Authors:  Fengzhi Li; Michael G Brattain
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

2.  Calcineurin (CN) activation promotes apoptosis of glomerular podocytes both in vitro and in vivo.

Authors:  Liming Wang; Jae-Hyung Chang; Seung-Yeol Paik; Yuping Tang; William Eisner; Robert F Spurney
Journal:  Mol Endocrinol       Date:  2011-05-26

3.  Inhibition of human neuroblastoma in SCID mice by low-dose of selective Cox-2 inhibitor nimesulide.

Authors:  Bhupesh Parashar; Bridget Shafit-Zagardo
Journal:  J Neurooncol       Date:  2006-03-22       Impact factor: 4.130

Review 4.  Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?

Authors:  Zhongxing Liao; Kathryn A Mason; Luka Milas
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Dynamic simulations on the arachidonic acid metabolic network.

Authors:  Kun Yang; Wenzhe Ma; Huanhuan Liang; Qi Ouyang; Chao Tang; Luhua Lai
Journal:  PLoS Comput Biol       Date:  2007-02-07       Impact factor: 4.475

6.  Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor.

Authors:  Paramahamsa Maturu; Devin Jones; E Cristy Ruteshouser; Qianghua Hu; Joseph M Reynolds; John Hicks; Nagireddy Putluri; Suhendan Ekmekcioglu; Elizabeth A Grimm; Chen Dong; Willem W Overwijk
Journal:  Neoplasia       Date:  2017-03       Impact factor: 5.715

7.  Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors.

Authors:  Paramahamsa Maturu; Willem W Overwijk; John Hicks; Suhendan Ekmekcioglu; Elizabeth A Grimm; Vicki Huff
Journal:  Transl Oncol       Date:  2014-06-23       Impact factor: 4.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.